FDA OKs Xeomin in fourth in­di­ca­tion; Nextbi­otix rais­es $8M for mi­cro­bio­me tech

→ The FDA has green-light­ed Merz North Amer­i­ca’s sup­ple­men­tal Bi­o­log­ics Li­cense Ap­pli­ca­tion (sBLA) for Xeomin for the treat­ment of ex­ces­sive drool­ing (chron­ic sial­or­rhea) in adult pa­tients. Drool­ing is a com­mon symp­tom among pa­tients who suf­fer from neu­ro­log­i­cal dis­or­ders in­clud­ing Parkin­son’s dis­ease, ALS, cere­bral pal­sy and stroke. Merz says Xeomin is the first and on­ly neu­ro­tox­in with this ap­proved in­di­ca­tion in the US. This is the fourth neu­ro­log­i­cal in­di­ca­tion for Xeomin, which was first ap­proved by the FDA in 2010.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER